Journal of the Neurological Sciences最新文献_第2页

The effect of cerebral collateral recycle on outcomes for patients with large ischemic infarct undergoing endovascular treatment 脑侧支循环对血管内治疗大面积缺血性梗死患者预后的影响

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-14 DOI: 10.1016/j.jns.2025.123538

Zhiyuan Wang , Shuyu Jiang , Chen Gong , Zhongsong Xiao , Liping Huang , Lihong Wen , Yi Luo , Yunyi Huang , Yuetao Wen , Zhiyu Xiong , Ziyi Li , Jin Liu , Jing Guo , Shengli Chen , Tao Xu , Yangmei Chen

{"title":"The effect of cerebral collateral recycle on outcomes for patients with large ischemic infarct undergoing endovascular treatment","authors":"Zhiyuan Wang , Shuyu Jiang , Chen Gong , Zhongsong Xiao , Liping Huang , Lihong Wen , Yi Luo , Yunyi Huang , Yuetao Wen , Zhiyu Xiong , Ziyi Li , Jin Liu , Jing Guo , Shengli Chen , Tao Xu , Yangmei Chen","doi":"10.1016/j.jns.2025.123538","DOIUrl":"10.1016/j.jns.2025.123538","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Although several large clinical trials have shown that endovascular treatment (EVT) is beneficial for patients with large core infarction, their outcomes were still much worse than those with mild infarction. Therefore, given the cerebral collateral recycle (CCR) as an effective prognostic marker, this study explored the relationship between CCR and clinical outcomes in patients with large ischemic infarct.</div></div><div><h3>Methods</h3><div>We conducted a retrospective multicenter cohort study of patients with acute ischemic stroke due to large vessel occlusion (AIS-LVO). Extensive baseline infarction was defined by ASPECTS ≤5 on admission computed tomography (CT). CCR was determined by quantifying pial arterial collaterals and venous outflow (VO) based on admission CT angiography. Patients were divided into two groups by CCR status. The primary outcomes was the favorable outcomes (90-day modified Rankin Scale score of ≤3).</div></div><div><h3>Results</h3><div>Among 860 AIS-LVO patients receiving EVT, 140 patients met the inclusion criteria. In multivariable binary logistic regression analysis, compared with the unfavorable CCR group, the favorable CCR group had a higher rate of favorable outcomes at 90 days (84.62 % vs 32.46 %, aOR 8.08, 95 % CI 2.13–30.62, <em>P</em> = .002). In a subgroup analysis, similar results were found that favorable CCR group achieved a higher proportion of 90-day mRS 0–3.</div></div><div><h3>Conclusions</h3><div>The favorable collateral circulation including arterial inflow combined with venous outflow in AIS-LVO patients with extensive baseline infarction is associated with better clinical outcomes. CCR status could serve as a valuable imaging biomarker for outcomes prediction.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"474 ","pages":"Article 123538"},"PeriodicalIF":3.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of prognostic scores for functional outcome after ischemic stroke 缺血性脑卒中后功能预后评分的比较分析

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-13 DOI: 10.1016/j.jns.2025.123539

Fumi Irie , Koutarou Matsumoto , Ryu Matsuo , Yoshinobu Wakisaka , Tetsuro Ago , Takanari Kitazono , Masahiro Kamouchi , Fukuoka Stroke Registry Investigators

{"title":"Comparative analysis of prognostic scores for functional outcome after ischemic stroke","authors":"Fumi Irie , Koutarou Matsumoto , Ryu Matsuo , Yoshinobu Wakisaka , Tetsuro Ago , Takanari Kitazono , Masahiro Kamouchi , Fukuoka Stroke Registry Investigators","doi":"10.1016/j.jns.2025.123539","DOIUrl":"10.1016/j.jns.2025.123539","url":null,"abstract":"<div><h3>Background</h3><div>Comparative data on the predictive performance of stroke prognostic scores in a real-world setting are sparse.</div></div><div><h3>Objective</h3><div>We aimed to compare the performance of existing scores for acute stroke outcomes in an observational cohort.</div></div><div><h3>Methods</h3><div>Using data from 12,486 patients with acute ischemic stroke (mean [SD] age, 72.5 [12.6] years; male, 59.4 %) prospectively registered in Fukuoka, Japan, between 2007 and 2017, we evaluated the predictive performance of six stroke prognostic scores, namely ASTRAL, iScore, PLAN, HIAT, SPAN-100, and THRIVE. The discriminative power of the scores was evaluated by the area under the receiver operating characteristic curve (AUROC). Calibration was evaluated using calibration plots. Overall performance, incorporating both discrimination and calibration, was assessed using Brier score.</div></div><div><h3>Results</h3><div>In comparative analyses using un identical study population, AUROCs for predicting 3-month poor functional outcome were 0.87 for ASTRAL, 0.88 for iScore, and 0.89 for PLAN among the scores for all patients, and 0.74 for HIAT, 0.81 for SPAN-100, and 0.78 for THRIVE among the scores for patients receiving reperfusion therapy. The calibration plots showed fair agreement between the outcome predictions and the observed outcomes in all scores, and no substantial difference was found among the scores. The analysis of overall performance indicated that PLAN was better than ASTRAL, whereas no significant difference was found among HIAT, SPAN-100, and THRIVE.</div></div><div><h3>Conclusions</h3><div>The predictive performance of all six scores was good, even in our observational cohort, reflecting the real-world setting. The prognostic scores could provide useful information for the management of acute stroke patients.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"474 ","pages":"Article 123539"},"PeriodicalIF":3.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of the sequelae of post Covid-19 with neurological implications (post-viral syndrome) 新型冠状病毒感染后的后遗症（病毒后综合征）研究进展

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-12 DOI: 10.1016/j.jns.2025.123532

Walter Struhal, Doaa Almamoori

{"title":"A review of the sequelae of post Covid-19 with neurological implications (post-viral syndrome)","authors":"Walter Struhal, Doaa Almamoori","doi":"10.1016/j.jns.2025.123532","DOIUrl":"10.1016/j.jns.2025.123532","url":null,"abstract":"<div><div>Post Covid-19 conditions represent a medical challenge; a unified definition is not achieved after 5 years of the Pandemic.</div><div>The incidence of Post Covid-19 conditions varies, nevertheless the neurological complications represent an important aspect in the spectrums of fields involved.</div><div>The current perception is that varied manifestations and long-term complications of COVID-19 reflect underlying pathophysiological processes, including inflammatory, immune-mediated, and vascular mechanisms. These mechanisms underscore the complexity of COVID-19's impact including the nervous system and its potential for lasting effects.</div><div>A number of symptoms are extremely severe and may also need neurologic attention including fatigue, cognitive disturbances, autonomic symptoms, headache, and sleep disorders.</div><div>Post Covid-19 conditions are often of chronic nature. Management as in other chronic conditions should rely on the conventional diagnostic measures and management of symptoms irrespective of the temporal relation to the viral infection. To date Post Covid-19 conditions is only accepted as an additional or explanatory diagnosis.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"474 ","pages":"Article 123532"},"PeriodicalIF":3.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144084178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus Ocrevus治疗多发性硬化症患者的病毒特异性抗体反应

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-12 DOI: 10.1016/j.jns.2025.123537

Nadia Zivlaei , Daut Can Asani , Nicole Hartwig Trier , Danguolė Žiogienė , Alma Gedvilaitė , Rasa Petraitytė Burneikienė , Evaldas Ciplys , Rimantas Slibinskas , Gunnar Houen , Jette Lautrup Frederiksen

{"title":"Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus","authors":"Nadia Zivlaei , Daut Can Asani , Nicole Hartwig Trier , Danguolė Žiogienė , Alma Gedvilaitė , Rasa Petraitytė Burneikienė , Evaldas Ciplys , Rimantas Slibinskas , Gunnar Houen , Jette Lautrup Frederiksen","doi":"10.1016/j.jns.2025.123537","DOIUrl":"10.1016/j.jns.2025.123537","url":null,"abstract":"<div><div>Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. B cell-depleting therapy is highly efficient in treating patients with relapsing-remitting MS (RRMS), although the mechanisms behind reducing disease progression with this type of therapy is unknown. Virus infections are associated with the onset of MS and antibodies to these have previously been suggested to supplement MS diagnostics. Based on this, we aimed to investigate the effect of Ocrevus (OCR) (B cell depletion therapy) on selected virus antibody levels.</div><div>Blood samples were collected from RRMS patients before (<em>n</em> = 13) and during OCR treatment (<em>n</em> = 29) and from healthy controls (HCs) (<em>n</em> = 15). Serum antibodies to virus antigens from Epstein-Barr virus (EBV), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), Rubella virus, Measles virus, John Cunningham polyomavirus, Mumps virus, Merkel cell polyomavirus, Varicella zoster virus, Influenza A virus, Human herpes virus 6, and Cytomegalovirus were analyzed by enzyme-linked immunosorbent assay.</div><div>EBV nuclear antigen 1 (EBNA1) IgG levels were elevated in RRMS patients compared to HCs independent of OCR treatment. However, no significant difference in virus antibody levels was observed following OCR treatment. Only SARS-CoV-2 spike protein IgG levels were significantly reduced following OCR treatment. The effect of OCR treatment on antibody levels may correlate with the time of infection. Only EBV EBNA1 IgG levels were significantly elevated RRMS patients at baseline compared to HCs, supporting that EBV infection is involved in the development of MS and confirming the diagnostic value of EBNA1 IgG.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"474 ","pages":"Article 123537"},"PeriodicalIF":3.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small fiber neuropathy following COVID-19 vaccination: A case series COVID-19疫苗接种后小纤维神经病变：病例系列

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-11 DOI: 10.1016/j.jns.2025.123536

Giulia Carolina Primicerio , Margrethe B. Bille , Eva Løbner Lund , Steffen Birk

引用次数: 0

TARDBP variants in Taiwanese ALS patients: Genetic spectrum, clinical features, and founder effects

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-10 DOI: 10.1016/j.jns.2025.123531

Kang-Yang Jih , Shih-Yu Fang , Yu-Sheun Tsai , Hou-Ping Sytwu , Yi-Chu Liao , Yi-Chung Lee

{"title":"TARDBP variants in Taiwanese ALS patients: Genetic spectrum, clinical features, and founder effects","authors":"Kang-Yang Jih , Shih-Yu Fang , Yu-Sheun Tsai , Hou-Ping Sytwu , Yi-Chu Liao , Yi-Chung Lee","doi":"10.1016/j.jns.2025.123531","DOIUrl":"10.1016/j.jns.2025.123531","url":null,"abstract":"<div><h3>Background</h3><div><em>TARDBP</em> is one of the most commonly implicated genes in amyotrophic lateral sclerosis (ALS). It encodes TAR DNA-binding protein 43 (TDP-43), a protein critical to ALS pathology, whose pathogenic variants disrupt its nuclear-cytoplasmic translocation, leading to aggregation. This study aimed to investigate the role of <em>TARDBP</em> variants in a Taiwanese ALS cohort.</div></div><div><h3>Methods</h3><div>We analyzed the coding regions of <em>TARDBP</em> using Sanger sequencing in 650 unrelated ALS patients recruited between 2000 and 2024. The cohort included 388 men and 262 women, with an average age of onset of 56 ± 13 years. Approximately 20 % presented with bulbar-onset ALS. Haplotype analysis was conducted using single nucleotide polymorphism and short tandem repeat markers flanking <em>TARDBP</em>.</div></div><div><h3>Results</h3><div>Pathogenic <em>TARDBP</em> variants were identified in 17 probands and 11 of their relatives, with an average age of onset of 49.1 ± 10.3 years, 32 % of whom had bulbar-onset disease. Six probands carried the p.M337V variant, five had p.S375G, two had p.N378D, and one each carried p.G348C, p.G348V, p.G376D, or p.I383V. Haplotype analysis suggested a common founder for the p.S375G variant and most families with p.M337V. Asymptomatic carriers were also identified, suggesting incomplete penetrance.</div></div><div><h3>Conclusions</h3><div>Our study revealed that pathogenic <em>TARDBP</em> variants are a significant genetic contributor to ALS in Taiwan, associated with earlier disease onset but reduced penetrance. The recurrent M337V and p.S375G variants likely reflect a founder effect.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"474 ","pages":"Article 123531"},"PeriodicalIF":3.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study 从fingolimod切换到siponimod的安全性评估：一项意大利多中心前瞻性研究

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-10 DOI: 10.1016/j.jns.2025.123533

Gianmarco Abbadessa , Irene Schiavetti , Luca Bollo , Maria Cellerino , Giuseppina Miele , Aurora Zanghì , Paola Cavalla , Alessio Signori , Alessandro Bulgari , Maria Trotta , Valentina Scarano , Roberta Fantozzi , Doriana Landi , Krzysztof Smolik , Valentina Torri Clerici , Giovanna De Luca , Fabiana Marinelli , Fabio Buttari , Marinella Clerico , Gina Ferrazzano , Simona Bonavita

{"title":"Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study","authors":"Gianmarco Abbadessa , Irene Schiavetti , Luca Bollo , Maria Cellerino , Giuseppina Miele , Aurora Zanghì , Paola Cavalla , Alessio Signori , Alessandro Bulgari , Maria Trotta , Valentina Scarano , Roberta Fantozzi , Doriana Landi , Krzysztof Smolik , Valentina Torri Clerici , Giovanna De Luca , Fabiana Marinelli , Fabio Buttari , Marinella Clerico , Gina Ferrazzano , Simona Bonavita","doi":"10.1016/j.jns.2025.123533","DOIUrl":"10.1016/j.jns.2025.123533","url":null,"abstract":"<div><h3>Introduction</h3><div>Safety concerns have been raised regarding fingolimod to siponimod transition in people with Secondary Progressive Multiple Sclerosis (SPMS).</div></div><div><h3>Objective</h3><div>To explore factors associated with the choice of switching from fingolimod to siponimod and the safety of this sequencing.</div></div><div><h3>Methods</h3><div>We conducted a prospective observational study that included patients who had a confirmed diagnosis of SPMS at the time of study entry and had been treated with fingolimod for at least two years. Upon enrollment, patients either continued fingolimod (comparator group) or transitioned to siponimod (switch group) and were followed up for six months to assess disease activity and changes in laboratory parameters.</div></div><div><h3>Results</h3><div>Out of 95 SPMS subjects, 42 (44.2 %) switched to siponimod at study entry. The switch group was younger and had more prior treatments than the comparator group (<em>p</em> = 0.042 and <em>p</em> = 0.015, respectively). Five subjects experienced disease activity (three in the switch group, two in the comparator). Patients switching to siponimod experienced a greater increase in GPT (p = 0.015) and GOT levels (<em>p</em> = 0.041) at 6 months. Four adverse events were reported: melanoma and grade IV lymphopenia in the comparator group, and grade IV lymphopenia and dizziness in the switch group.</div></div><div><h3>Conclusion</h3><div>During the 6-month observation period, switching from fingolimod to siponimod was safe in terms of disease reactivation and tolerability.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"474 ","pages":"Article 123533"},"PeriodicalIF":3.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of cerebral venous thrombosis with and without COVID-19 infection 合并和不合并COVID-19感染的脑静脉血栓的结局

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-09 DOI: 10.1016/j.jns.2025.123529

Rohan Arora , Pavitra Srinivasan , Omnia Omprakash , Varalakshmi Ballur Narayana Reddy , Nandakumar Nagaraja

{"title":"Outcomes of cerebral venous thrombosis with and without COVID-19 infection","authors":"Rohan Arora , Pavitra Srinivasan , Omnia Omprakash , Varalakshmi Ballur Narayana Reddy , Nandakumar Nagaraja","doi":"10.1016/j.jns.2025.123529","DOIUrl":"10.1016/j.jns.2025.123529","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to compare outcomes of cerebral venous thrombosis (CVT) within 2 weeks of coronavirus disease-2019 (COVID-19) infection compared to those without COVID-19.</div></div><div><h3>Methods</h3><div>The study included adult patients diagnosed with CVT between 2020 and 2022 in TriNetX COVID research network. They were categorized into two groups namely, CVT with COVID and CVT without COVID, based on diagnosis of COVID-19 infection within 2 weeks of CVT diagnosis. All-cause mortality, cerebrovascular and thromboembolic outcomes were assessed at one and three months. Propensity score matching was performed to control for covariates. The two groups were compared with cox proportional hazard analysis and reported as hazard ratio (HR) and 95 % confidence interval (CI).</div></div><div><h3>Results</h3><div>547 patients with CVT and COVID and 10,450 patients with CVT without COVID met the study criteria. After matching, 544 patients were in each group. Patients with COVID-19 infection within 2 weeks prior to CVT diagnosis had twice higher risk of all-cause mortality [1 month: 35 (6.4 %) vs 15 (2.8 %); HR = 2.37; 95 % CI = 1.30–4.35 and at three months: 51 (9.4 %) vs 21 (3.9 %); HR = 2.49; 95 % CI = 1.50–4.14] and higher risk of complications of intracerebral hemorrhage [1 month: 12.3 % vs 8.3 %; HR = 1.50; 95 % CI = 1.01–2.24) and three months: 12.8 % vs 8.7 %; HR = 1.49; 95 % CI = 1.01–2.19)] and pulmonary embolism [1 month: 5.6 % vs 2.2 %; HR = 2.63; 95 % CI = 1.31–5.27 and 3 months: 6.0 % vs 2.5 %; HR = 2.39; 95 % CI = 1.25–4.59] compared to CVT without COVID.</div></div><div><h3>Conclusion</h3><div>COVID-19 infection increases risk of mortality, intracerebral hemorrhage and pulmonary embolism in patients with CVT.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"474 ","pages":"Article 123529"},"PeriodicalIF":3.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143950418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The World Federation of Neurology: Brain health for all ages 2025 世界神经病学联合会：2025年所有年龄段的大脑健康

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-07 DOI: 10.1016/j.jns.2025.123530

Wolfgang Grisold, David Dodick, Alla Guekht, Steven Lewis, Ashley Logan, Tissa Wijnerate

引用次数: 0

Clinical, neurophysiological, and radiological characteristics of peripheral neuropathy in patients with rheumatoid arthritis: A cross-sectional observational study 类风湿性关节炎患者周围神经病变的临床、神经生理学和放射学特征：一项横断面观察研究

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2025-05-07 DOI: 10.1016/j.jns.2025.123523

Mennatallah Sayed Abdelrazek , Basma Mohamed Ali Elnaggar , Ali Mahmoud Ahmed , Maha Salah Eldin Mohamed

{"title":"Clinical, neurophysiological, and radiological characteristics of peripheral neuropathy in patients with rheumatoid arthritis: A cross-sectional observational study","authors":"Mennatallah Sayed Abdelrazek , Basma Mohamed Ali Elnaggar , Ali Mahmoud Ahmed , Maha Salah Eldin Mohamed","doi":"10.1016/j.jns.2025.123523","DOIUrl":"10.1016/j.jns.2025.123523","url":null,"abstract":"<div><div>Neural involvement contributes to body dysfunction and compromised life quality in patients with rheumatoid arthritis (RA). We aimed to investigate the incidence, pattern, associations, predictors and best diagnostic tools of peripheral neuropathy (PN) in RA patients. We recruited 586 RA patients. Patients were categorized into three groups based on the presence (either clinically or subclinical) or absence of PN. PN was found electro-physiologically in 396 patients, 348 with clinical evidence of PN and 48 without clinical evidence. There were significant correlations between PN development and age, disease duration, involved joints, subcutaneous nodule, and VAS score. The mean cross-sectional areas were 9.55 ± 2.35, 9.62 ± 2.28, 9.19 ± 2.51 and 9.16 ± 2.43 mm<sup>2</sup> in the right and left median and ulnar nerves, respectively. The number of affected small joints was an independent predictive factor of polyneuropathy and multiple mononeuropathy with an adjusted OR of 1.62 and 1.352, respectively. PN is highly prevalent in patients with RA, including those without overt symptoms or signs. It is highly associated with disease severity, disease duration, age, joint affection and erosion, VAS score and HAQ<img>D1. All types of PN could occur in RA. The US could be used for the diagnosis of PN in RA patients. The ultrasonographic references for the examined nerves were provided.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"473 ","pages":"Article 123523"},"PeriodicalIF":3.6,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143934649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0